Zevra Therapeutics, Inc. ZVRA Current portion of discount and rebate liabilities
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept zvra:DiscountAndRebateLiabilitiesCurrent.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s current portion of discount and rebate liabilities.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s current portion of discount and rebate liabilities?
- Zevra Therapeutics, Inc. (ZVRA) reported current portion of discount and rebate liabilities of $13.17M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s current portion of discount and rebate liabilities changed year-over-year?
- Zevra Therapeutics, Inc.'s current portion of discount and rebate liabilities increased by 154.9% year-over-year, from $5.17M to $13.17M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s current portion of discount and rebate liabilities?
- Over 3 years (2022 to 2025), Zevra Therapeutics, Inc.'s current portion of discount and rebate liabilities has grown at a 37.8% compound annual growth rate (CAGR), from $4.66M to $12.19M.